AVAC comments submitted to the Antimicrobial Drugs Advisory Committee and FDA re: TAF/FTC (Descovy) as PrEP, which encourage the Advisory Committee to recommend, and the FDA to approve, the supplemental indication for daily oral PrEP with F/TAF for adult men and women at risk of sexually acquired HIV-1 infection – with the appropriate requirements for labeling, post-marketing surveillance and REMS as described in the letter, and as per the FDA’s own updated guidance on REMS and access posted earlier this year.
AVAC Comments to Antimicrobial Drugs Advisory Committee and FDA re: TAF/FTC (Descovy) as PrEP
Hormonal Contraceptive Methods and HIV: Research gaps and programmatic priorities
This article in Contraception summarizes key findings and conclusions from a December 2015 meeting convened by WHO on the research agenda for hormonal contraception and HIV.
Next steps for PrEP: Getting a proven prevention option to the people who need it
An article from the June 2013 edition of the GMHC newsletter discussing issues of PrEP introduction worldwide, reviewing efficacy trial results and current status of regulatory approval of Truvada as PrEP and rollout efforts.